Ivax Launches Neurontin Generic As User Fee Date For Pfizer's Pregabalin Nears
This article was originally published in The Pink Sheet Daily
Executive Summary
Non-AB-rated gabapentin tablets launch "at risk" less than two weeks before the estimated Aug. 30 user fee deadline for Pfizer's follow-on drug Lyrica. Pfizer is seeking a temporary restraining order against Ivax.
You may also be interested in...
FDA Should Deem Atorvastatin Capsule ANDAs Suitable For Submission – Citizen Petition
Atorvastatin capsules would be bioequivalent to Pfizer’s Lipitor tablets since the dosage form is the only proposed change to labeling, Lachman Consultant Services says in citizen petition.
FDA Should Deem Atorvastatin Capsule ANDAs Suitable For Submission – Citizen Petition
Atorvastatin capsules would be bioequivalent to Pfizer’s Lipitor tablets since the dosage form is the only proposed change to labeling, Lachman Consultant Services says in citizen petition.
Purepac Free To Launch Neurontin Generic After Court Lifts Stay
The company is not commenting on launch plans but previously said it would "commence commercial sales" if a court stay was lifted. Purepac said it would book revenues from its own gabapentin generic upon launch, but revenues received under an agreement with Teva would not be recorded until patent litigation with Pfizer is resolved.